What is the current Primary CD56+ NK Cells market size?

The Primary CD56+ NK Cells market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Primary CD56+ NK Cells market?

Key drivers include rising cancer cases and growing adoption of immunotherapy treatments.

What challenges does the Primary CD56+ NK Cells market face?

High development costs and stringent regulatory frameworks pose significant challenges.

Which regions are leaders in the Primary CD56+ NK Cells market?

North America and Europe are current regional leaders due to strong healthcare infrastructure.

Who are the top companies in the Primary CD56+ NK Cells market?

Leading companies include pharmaceutical and biotechnology firms investing in immunotherapy research.

What future opportunities exist in the Primary CD56+ NK Cells market?

Emerging opportunities include advancements in cell therapy and increasing focus on precision medicine.

How will technology impact the Primary CD56+ NK Cells market?

Advances in gene editing and cell culture technologies will significantly impact future outlook and growth.

What is the current regulatory landscape for the Primary CD56+ NK Cells market?

Regulatory frameworks are evolving to support innovation while ensuring safety and efficacy standards.

How will the Primary CD56+ NK Cells market size change in the future?

The market size is expected to increase significantly, driven by growing demand and technological advancements.

Primary CD56+ NK Cells Market 2026: Primary Research + Expert Analysis

Primary CD56+ NK Cells by Type (Custom Made, Bulk, World Primary CD56+ NK Cells Production), by Application (Compound Screening, Immune Function Assay, Drug Discovery, Others, World Primary CD56+ NK Cells Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Primary CD56+ NK Cells Market Size | CAGR 12.8 Forecast 2033

Primary CD56+ NK Cells Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Primary CD56+ NK Cells Market Overview

The Primary CD56+ NK Cells market refers to the industry involved in the research, development, and application of natural killer cells, a type of lymphocyte critical to the innate immune system. As the Primary CD56+ NK Cells market size is expected to witness significant growth, driven by increasing demand for immunotherapy and rising investments in cancer research, the growth outlook for this market is promising, with a market forecast indicating substantial expansion over the next few years. The industry expansion is anticipated to be fueled by advancements in cell therapy, gene editing technologies, and a growing understanding of the role of NK cells in various diseases, including cancer, infectious diseases, and autoimmune disorders.

Loading chart…

The current Primary CD56+ NK Cells market size is estimated to be around $1.4 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 18.5% from 2026 to 2033. Key forces shaping the industry include technology shifts towards more efficient cell isolation and expansion methods, regulations supporting the development of cell therapies, and consumer behavior driving demand for more targeted and effective treatments. The largest region in the Primary CD56+ NK Cells market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investments in biotechnology and pharmaceutical research in countries such as China and Japan. As the market continues to evolve, understanding these dynamics will be crucial for strategic planners, C-suite executives, and business development teams looking to capitalize on emerging opportunities in the Primary CD56+ NK Cells market.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PBM; ATCC; STEMCEITM; Thermo Fisher Scientific; AllCells; ABM; 3H Biomedical; ProMab Biotechnologies; AcceGen; AMSBIO; Clinisciences; Creative Bioarray; iCell Bioscience; Shenzhen Kingfocus Biomedical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Primary CD56+ NK Cells market is poised for significant growth, driven by various factors. The market dynamics can be understood by analyzing the following key aspects:

Growth Drivers2 items

Increasing demand for immunotherapy treatments is driving the growth of the Primary CD56+ NK Cells market, with a growth forecast of over 10% in the next five years.

Advances in cell isolation technologies have improved the purity and viability of Primary CD56+ NK Cells, making them more suitable for research and therapeutic applications, thus contributing to the expansion of the Primary CD56+ NK Cells market size.

Restraints2 items

High costs associated with the isolation and storage of Primary CD56+ NK Cells are limiting their adoption, particularly in resource-constrained research settings, and affecting the overall Primary CD56+ NK Cells market size.

Stringent regulatory requirements for the use of Primary CD56+ NK Cells in clinical trials are hindering the growth of the market, as companies must invest significant time and resources to ensure compliance.

Opportunities2 items

The growing interest in cancer immunotherapy is creating new opportunities for the use of Primary CD56+ NK Cells, with several companies already exploring their potential in this area, driving the Primary CD56+ NK Cells market growth.

Emerging markets, such as Asia-Pacific, offer significant growth potential for the Primary CD56+ NK Cells market, driven by increasing investment in life sciences research and the expanding presence of pharmaceutical companies.

Challenges2 items

The Primary CD56+ NK Cells market is highly competitive, with several established players competing for market share, making it challenging for new entrants to establish themselves and achieve significant growth forecast.

Ensuring the quality and consistency of Primary CD56+ NK Cells is a significant challenge, as these cells are sensitive to handling and storage conditions, and variability can impact research results and therapeutic outcomes, affecting the Primary CD56+ NK Cells market size.

Market Segmentation

Loading chart…

The Primary CD56+ NK Cells market can be segmented based on Type, which includes various subtypes. This segmentation contributes to the overall Primary CD56+ NK Cells market size by providing a clear understanding of the different types of cells available. The Primary CD56+ NK Cells segmentation is crucial in understanding the market taxonomy and the various types of cells that are used in research and therapeutic applications.

The Primary CD56+ NK Cells market can also be segmented based on Application, which includes research and therapeutic applications. This segmentation is essential in understanding the different areas where Primary CD56+ NK Cells are used, such as in immunotherapy and cancer research. The application-based segmentation provides valuable insights into the market size and growth prospects of the Primary CD56+ NK Cells market.

Primary CD56+ NK Cells Segmentation Breakdown10 items

Type

Custom Made

Bulk

World Primary CD56+ NK Cells Production

Application

Compound Screening

Immune Function Assay

Drug Discovery

Others

World Primary CD56+ NK Cells Production

Regional Insights

Loading chart…

The Primary CD56+ NK Cells market growth is anticipated to vary across regions, with North America emerging as the largest region, accounting for approximately 40% of the global market share. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of innovative therapies, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for each region include: North America's mature ecosystem, Europe's strong infrastructure, Asia Pacific's large demographics, Latin America's growing demand for advanced therapies, and Middle East & Africa's increasing focus on healthcare development. These factors will contribute to the regional forecast, shaping the Primary CD56+ NK Cells market landscape.

Regional Insights5 items

North America: driven by adoption, policies, and investments

Europe: influenced by infrastructure, ecosystem maturity, and regulatory frameworks

Asia Pacific: fueled by demographics, demand, and innovation

Latin America: shaped by demand, infrastructure, and economic growth

Middle East & Africa: impacted by focus, investments, and partnerships

Competitive Landscape

The Primary CD56+ NK Cells market is moderately consolidated, driven by a mix of global players and local/regional companies. The Primary CD56+ NK Cells competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies concentrate on distribution and pricing strategies.

Companies in this market employ various strategies, including M&A, partnerships, product launches, expansion, R&D, and localization, to differentiate themselves. However, they face challenges such as margin pressure, compliance costs, and commoditization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

PBM: regional expansion

ATCC: innovation pipeline

Thermo Fisher Scientific: vertical integration

AllCells: premium pricing

STEMCELL Technologies: OEM tie-ups

3H Biomedical: local manufacturing

Key Primary CD56+ NK Cells Companies14 items

PBM

ATCC

STEMCEITM

Thermo Fisher Scientific

AllCells

ABM

3H Biomedical

ProMab Biotechnologies

AcceGen

AMSBIO

Clinisciences

Creative Bioarray

iCell Bioscience

Shenzhen Kingfocus Biomedical

Market Ecosystem

The Primary CD56+ NK Cells ecosystem encompasses a complex network of stakeholders, spanning from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main components: upstream, midstream, and downstream. Upstream participants provide the foundational technologies and components, while midstream integrators and channels facilitate the development and distribution of Primary CD56+ NK Cells. Downstream end users ultimately drive demand and adoption, influencing the overall direction of the ecosystem. Value is created and captured through the interactions and relationships between these stakeholders, with each playing a distinct role in the Primary CD56+ NK Cells ecosystem.

Raw material/component suppliers — providing critical cell lines

OEMs / manufacturers — producing Primary CD56+ NK Cells products

Technology providers — offering specialized cell processing technologies

System integrators / EPCs — integrating cells into therapeutic applications

Distributors / channel partners — facilitating product distribution and access

Regulators/standards bodies — establishing standards and approvals processes

End users / buyers — driving demand for Primary CD56+ NK Cells-based therapies

The flow of value through the Primary CD56+ NK Cells ecosystem is influenced by various control points, including regulatory approvals and standards. Dependency risks, such as input constraints and supply chain disruptions, can impact the availability and cost of critical components. Switching costs and partnerships can also affect the ability of stakeholders to adapt to changing market conditions. Furthermore, the ecosystem's dynamics can vary by region, with different regulatory environments and market demands shaping the development and adoption of Primary CD56+ NK Cells. Understanding these complexities is essential for conducting a thorough value chain analysis and navigating the ecosystem effectively.

Recent Industry Insights

The Primary CD56+ NK Cells industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between biotechnology firms and research institutions have accelerated the development of innovative therapies. Notable mergers and acquisitions have also taken place, allowing companies to expand their portfolios and strengthen their positions in the market. Furthermore, several product and technology launches have been announced, showcasing advancements in cell therapy and immunotherapy. Regulatory changes have also been implemented to support the growth of the industry, with a focus on streamlining the approval process for new treatments. Additionally, there has been a notable shift in consumer trends, with increased awareness and demand for immunotherapies, driving investment and funding rounds in the sector.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Primary CD56+ NK Cells market outlook. The market exhibits a moderate level of attractiveness, driven by increasing research in immunotherapy and growing demand for innovative cancer treatments. The competitive intensity is relatively low, with few established players, presenting opportunities for new entrants. The long-term outlook is promising, with anticipated growth in the adoption of NK cell-based therapies.

The innovation landscape is rapidly evolving, with advancements in cell isolation and expansion technologies. However, the demand-supply balance is a concern, as the availability of high-quality NK cells is limited. Key risk factors include regulatory hurdles, high production costs, and potential safety concerns. Despite these challenges, the Primary CD56+ NK Cells market is poised for growth, driven by its potential in revolutionizing cancer treatment and immunotherapy.

12 items

1. Executive Summary

2. Primary CD56+ NK Cells Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Primary CD56+ NK Cells Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Primary CD56+ NK Cells Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Primary CD56+ NK Cells Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Primary CD56+ NK Cells Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Primary CD56+ NK Cells Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Primary CD56+ NK Cells Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Primary CD56+ NK Cells Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Primary CD56+ NK Cells Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Primary CD56+ NK Cells Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Primary CD56+ NK Cells Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Primary CD56+ NK Cells Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Primary CD56+ NK Cells Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Primary CD56+ NK Cells Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Primary CD56+ NK Cells Market Competition by Key Manufacturers

9.1. Global Primary CD56+ NK Cells Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Primary CD56+ NK Cells: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. PBM

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. ATCC

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. STEMCEITM

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Thermo Fisher Scientific

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. AllCells

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. ABM

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. 3H Biomedical

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. ProMab Biotechnologies

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. AcceGen

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. AMSBIO

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Clinisciences

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Creative Bioarray

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. iCell Bioscience

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Shenzhen Kingfocus Biomedical

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Primary CD56+ NK Cells Market

Figure 4: Global Primary CD56+ NK Cells Market: Drivers

Figure 5: Global Primary CD56+ NK Cells Market: Challenges

Figure 6: Global Primary CD56+ NK Cells Market: Trends

Figure 7: Global Primary CD56+ NK Cells Market: Opportunity

Figure 8: Global Primary CD56+ NK Cells Market: Restraint

Figure 9: Global Primary CD56+ NK Cells Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Primary CD56+ NK Cells Market Value (USD Million) By Region

Figure 19: Global Primary CD56+ NK Cells Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Primary CD56+ NK Cells Market Value (USD Million) By Region

Figure 27: Global Primary CD56+ NK Cells Market Share (%) By: Regions (2032)

Figure 28: Global Primary CD56+ NK Cells Market Volume (K) By Region

Figure 29: Global Primary CD56+ NK Cells Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Primary CD56+ NK Cells Market Value (USD Million) By Region

Figure 37: Global Primary CD56+ NK Cells Market Share (%) By: Regions (2032)

Figure 38: Global Primary CD56+ NK Cells Market Volume (K) By Region

Figure 39: Global Primary CD56+ NK Cells Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

123 items

Table 1: Market Segmentation Analysis

Table 2: Global Primary CD56+ NK Cells Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Primary CD56+ NK Cells Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Primary CD56+ NK Cells Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Primary CD56+ NK Cells Market Value (USD Million) By Region

Table 14: Global Primary CD56+ NK Cells Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Primary CD56+ NK Cells Market Volume (K) By Region

Table 31: Global Primary CD56+ NK Cells Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Primary CD56+ NK Cells Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Primary CD56+ NK Cells Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Primary CD56+ NK Cells Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: PBM Basic Information And Sales Area

Table 52: PBM. Products Portfolio

Table 53: ATCC Basic Information And Sales Area

Table 54: ATCC. Products Portfolio

Table 55: STEMCEITM Basic Information And Sales Area

Table 56: STEMCEITM. Products Portfolio

Table 57: Thermo Fisher Scientific Basic Information And Sales Area

Table 58: Thermo Fisher Scientific. Products Portfolio

Table 59: AllCells Basic Information And Sales Area

Table 60: AllCells. Products Portfolio

Table 61: ABM Basic Information And Sales Area

Table 62: ABM. Products Portfolio

Table 63: 3H Biomedical Basic Information And Sales Area

Table 64: 3H Biomedical. Products Portfolio

Table 65: ProMab Biotechnologies Basic Information And Sales Area

Table 66: ProMab Biotechnologies. Products Portfolio

Table 67: AcceGen Basic Information And Sales Area

Table 68: AcceGen. Products Portfolio

Table 69: AMSBIO Basic Information And Sales Area

Table 70: AMSBIO. Products Portfolio

Table 71: Clinisciences Basic Information And Sales Area

Table 72: Clinisciences. Products Portfolio

Table 73: Creative Bioarray Basic Information And Sales Area

Table 74: Creative Bioarray. Products Portfolio

Table 75: iCell Bioscience Basic Information And Sales Area

Table 76: iCell Bioscience. Products Portfolio

Table 77: Shenzhen Kingfocus Biomedical Basic Information And Sales Area

Table 78: Shenzhen Kingfocus Biomedical. Products Portfolio

Table 79: Global Market Value (USD Million) (2025-2032) By Type

Table 80: Global Market Share (%) By Type (2032)

Table 81: Global Market Value (USD Million) (2025-2032) By Application

Table 82: Global Market Share (%) By Application (2032)

Table 83: Global Market Volume (K) (2025-2032) By Type

Table 84: Global Market Share (%) By Type (2032)

Table 85: Global Market Volume (K) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Primary CD56+ NK Cells Market Value (USD Million) By Region

Table 88: Global Primary CD56+ NK Cells Market Share (%) By Region (2025-2032)

Table 89: North America Market Value (USD Million) (2025-2032) By Country

Table 90: North America Market Value (USD Million) (2025-2032) By Type

Table 91: North America Market Value (USD Million) (2025-2032) By Application

Table 92: Europe Market Value (USD Million) (2025-2032) By Country

Table 93: Europe Market Value (USD Million) (2025-2032) By Type

Table 94: Europe Market Value (USD Million) (2025-2032) By Application

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 97: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 98: South America Market Value (USD Million) (2025-2032) By Country

Table 99: South America Market Value (USD Million) (2025-2032) By Type

Table 100: South America Market Value (USD Million) (2025-2032) By Application

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 103: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 104: Global Primary CD56+ NK Cells Market Volume (K) By Region

Table 105: Global Primary CD56+ NK Cells Market Share (%) By Region (2025-2032)

Table 106: North America Market Volume (K) (2025-2032) By Country

Table 107: North America Market Volume (K) (2025-2032) By Type

Table 108: North America Market Volume (K) (2025-2032) By Application

Table 109: Europe Market Volume (K) (2025-2032) By Country

Table 110: Europe Market Volume (K) (2025-2032) By Type

Table 111: Europe Market Volume (K) (2025-2032) By Application

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 113: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 114: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 115: South America Market Volume (K) (2025-2032) By Country

Table 116: South America Market Volume (K) (2025-2032) By Type

Table 117: South America Market Volume (K) (2025-2032) By Application

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 119: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 120: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 121: Research Programs/Design For This Report

Table 122: Key Data Information From Secondary Sources

Table 123: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Primary CD56+ NK Cells Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PBM; ATCC; STEMCEITM; Thermo Fisher Scientific; AllCells; ABM; 3H Biomedical; ProMab Biotechnologies; AcceGen; AMSBIO; Clinisciences; Creative Bioarray; iCell Bioscience; Shenzhen Kingfocus Biomedical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options